SLS (SELLAS Life Sciences Group) Total Stockholders Equity: $107.41 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLS SELLAS Life Sciences Group Inc SLS
25 GF Score
Price $13.16
View Full Analysis

What is SELLAS Life Sciences Group Total Stockholders Equity?

SELLAS Life Sciences Group SLS +4.16% 25 Total Stockholders Equity is $107.41 Mil as of Mar. 2026. GuruFocus rates SLS with a GF Score™ of 25/100.

SELLAS Life Sciences Group's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $107.41 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. SELLAS Life Sciences Group's Book Value per Share for the quarter that ended in Mar. 2026 was $0.59. The ratio of a company's debt over equity can be used to measure how leveraged this company is. SELLAS Life Sciences Group's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.01.

SELLAS Life Sciences Group  (NAS:SLS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

SELLAS Life Sciences Group's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(107.412-0)/181.333
=0.59

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

SELLAS Life Sciences Group's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.562 + 0.309) / 107.412
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SELLAS Life Sciences Group Total Stockholders Equity Related Terms

SELLAS Life Sciences Group Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for SELLAS Life Sciences Group's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SELLAS Life Sciences Group Total Stockholders Equity Chart

SELLAS Life Sciences Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.35 4.85 -7.98 9.47 70.87

SELLAS Life Sciences Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.76 26.15 45.63 70.87 107.41
SLS
25GF Score
SELLAS Life Sciences Group Inc SLS
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $107.41 Mil mean?
SELLAS Life Sciences Group (SLS) has a Total Stockholders Equity of $107.41 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for SELLAS Life Sciences Group and its competitors.
Is SELLAS Life Sciences Group's Total Stockholders Equity too high?
SELLAS Life Sciences Group's current Total Stockholders Equity is $107.41 Mil. Overall, SELLAS Life Sciences Group has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's Total Stockholders Equity compare to MBX and BHVN?
SELLAS Life Sciences Group's Total Stockholders Equity of $107.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for SELLAS Life Sciences Group and its competitors. SELLAS Life Sciences Group's current Total Stockholders Equity is $107.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current Total Stockholders Equity of $107.41 Mil. The current Total Stockholders Equity is $107.41 Mil. SELLAS Life Sciences Group's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current Total Stockholders Equity is $107.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SELLAS Life Sciences Group Business Description

Other Exchanges RXK3:Germany
Address 7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
25GF Score

Get the complete analysis for SLS

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.16
Price